Related references
Note: Only part of the references are listed.Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis
Natalia Mena-Vazquez et al.
CLINICAL RHEUMATOLOGY (2021)
Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development
Foteini Karakontaki et al.
AUTOIMMUNITY REVIEWS (2021)
Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis
Annalisa Fui et al.
INTERNAL MEDICINE JOURNAL (2020)
Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study
Andreina Manfredi et al.
INTERNAL MEDICINE JOURNAL (2020)
Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study
Eun Ha Kang et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjogren's syndrome: A systematic review from the Italian Society of Rheumatology
Gianluca Sambataro et al.
AUTOIMMUNITY REVIEWS (2020)
Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review
Mattia Bellan et al.
AUTOIMMUNITY REVIEWS (2020)
Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study
Sarah K. Chen et al.
ARTHRITIS CARE & RESEARCH (2020)
Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry
Cristina Vadillo et al.
RHEUMATOLOGY (2020)
Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study
Giulia Cassone et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis
Jun K. Khoo et al.
RHEUMATOLOGY (2020)
Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients
Carlos Fernandez-Diaz et al.
RHEUMATOLOGY (2020)
Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease
Javier Narvaez et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review
Belen Atienza-Mateo et al.
JOURNAL OF CLINICAL MEDICINE (2020)
The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis
Christopher R. Holroyd et al.
RHEUMATOLOGY (2019)
Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
Masayoshi Harigai
RHEUMATOLOGY (2019)
The effect of non-TNF-targeted biologics on vascular dysfunction in rheumatoid arthritis: A systematic literature review
Francesco Ursini et al.
AUTOIMMUNITY REVIEWS (2019)
The lung in a cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment
Ana C. Duarte et al.
RHEUMATOLOGY (2019)
Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts
Patrick Kiely et al.
BMJ OPEN (2019)
Interstitial lung disease associated with anti-PM-Scl antibody: A single center experience
Kamonpun Ussavarungsi et al.
AUTOIMMUNITY REVIEWS (2019)
Systemic rheumatic diseases: From biological agents to small molecules
Piercarlo Sarzi-Puttini et al.
AUTOIMMUNITY REVIEWS (2019)
Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Izumi Kurata et al.
INTERNAL MEDICINE (2019)
Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?
Ying Huang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature
George E. Fragoulis et al.
RHEUMATOLOGY (2019)
Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis
Thomas Barba et al.
AUTOIMMUNITY REVIEWS (2019)
Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents
Andrea Rubbert-Roth et al.
AUTOIMMUNITY REVIEWS (2019)
Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality
Karina Raimundo et al.
JOURNAL OF RHEUMATOLOGY (2019)
Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients
Carlos Fernandez-Diaz et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
The Lung in Rheumatoid Arthritis Focus on Interstitial Lung Disease
Paolo Spagnolo et al.
ARTHRITIS & RHEUMATOLOGY (2018)
T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis
Goncalo Boleto et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre
Md Yuzaiful Md Yusof et al.
RHEUMATOLOGY (2017)
Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
Katie L. Druce et al.
RMD OPEN (2017)
HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study
James Bluett et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality
Charlotte Hyldgaard et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis
Jorge Rojas-Serrano et al.
CLINICAL RHEUMATOLOGY (2017)
Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Joshua J. Solomon et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice
Takeshi Mochizuki et al.
MODERN RHEUMATOLOGY (2016)
Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials
Richard Conway et al.
JOURNAL OF RHEUMATOLOGY (2016)
Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
Masayoshi Harigai et al.
MODERN RHEUMATOLOGY (2016)
Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study
Mitsuhiro Akiyama et al.
RHEUMATOLOGY INTERNATIONAL (2016)
A case of acute respiratory failure in a rheumatoid arthritis patient after the administration of abatacept
Birsen Dogu et al.
EUROPEAN JOURNAL OF RHEUMATOLOGY (2016)
Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients
Tamao Nakashita et al.
RESPIRATORY INVESTIGATION (2016)
Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor a agents, a retrospective cohort study
Jeffrey R. Curtis et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Abatacept Therapy in Rheumatoid Arthritis With Interstitial Lung Disease
Antonio Mera-Varela et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2014)
Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan
Takao Koike et al.
JOURNAL OF RHEUMATOLOGY (2014)
Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA
Kumi Shidara et al.
Modern Rheumatology (2014)
Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
Takao Koike et al.
Modern Rheumatology (2014)
Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients
Takao Koike et al.
MODERN RHEUMATOLOGY (2014)
Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics-a large multicentre UK study
Clive A. Kelly et al.
RHEUMATOLOGY (2014)
Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review
Camille Roubille et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2014)
Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants
Simon L. F. Walsh et al.
THORAX (2014)
Methotrexate and Lung Disease in Rheumatoid Arthritis
Richard Conway et al.
ARTHRITIS & RHEUMATOLOGY (2014)
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
HLA-A*31:01 and methotrexate-induced interstitial lung disease in Japanese rheumatoid arthritis patients: a multidrug hypersensitivity marker?
Hiroshi Furukawa et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program
Michael E. Weinblatt et al.
JOURNAL OF RHEUMATOLOGY (2013)
Association between anti-TNF-α therapy and interstitial lung disease
Lisa J. Herrinton et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2013)
The Multifaceted Aspects of Interstitial Lung Disease in Rheumatoid Arthritis
Lorenzo Cavagna et al.
BIOMED RESEARCH INTERNATIONAL (2013)
A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab
Shin-ya Kawashiri et al.
RHEUMATOLOGY INTERNATIONAL (2012)
The effect of CTLA-4Ig, a CD28/B7 antagonist, on the lung inflammation and T cell subset profile during murine hypersensitivity pneumonitis
Luis Jimenez-Alvarez et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2011)
Non-infectious pulmonary complications of newer biological agents for rheumatic diseases-a systematic literature review
Andreas V. Hadjinicolaou et al.
RHEUMATOLOGY (2011)
Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases
Roberto Perez-Alvarez et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2011)
Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Incidence and Mortality of Interstitial Lung Disease in Rheumatoid Arthritis
Tim Bongartz et al.
ARTHRITIS AND RHEUMATISM (2010)
2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2010)
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
M. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis
Tetsuji Sawada et al.
RHEUMATOLOGY (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
T. Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis
Samy Suissa et al.
ARTHRITIS AND RHEUMATISM (2006)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
